Статья
ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ТЕРАПИИ ЭПРОСАРТАНОМ С ПОЗИЦИЙ «МЕДИЦИНЫ ДОКАЗАТЕЛЬСТВ»
Эффективность и безопасность терапии эпросартаномс позиций «медицины доказательств».
1. Harron D.W.G., Brogden R.N. Propafenone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cardiac arrhythmias. – Drugs, 1987; 34: 617-647.
2. Funck-Bentano C., Kroemer H.K., Lee J.T., Roden D.M. Propafenone. – New Engl. J. Med., 1990; 322: 518-525.
3. Veale D., McComb J.M., Gibson G.J. Propafenone. – Lancet, 1990; 335: 979-985..
4. Bryson H.M., Palmer K.J., Langtry H.D. et al. Propafenone: a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. – Drugs, 1993; 45 (1): 85-130.
5. Hii J.T.Y., Duff H.J., Burgess E.D. Clinical pharmacokinetics of propafenone. – Clin. Pharmacokinetics, 1991; 21: 1-10.
6. Axelson J.E., Chan G.L-Y., Kirsten E.B. et al. Food increase the bioavalability of propafenone. – Brit. J. Clin. Pharmacol., 1987; 23: 735-741.
7. Latini R., Marchi S., Riva E. et al. Distribution of propafenone and its active metabolites, 5-hydroxypropafenone. – Amer. Heart. J., 1987; 113: 843-846.
8. Boriani G., Strocchi E., Capucci A. et al. Relationships between debrisoqiune hydroxylation and propafenone pharmacokinenics. – Drug Invest., 1990; 2 (2): 114-119.
9. Kalow W. Ethnic differences of drug metabolism. – Drugs, 1982; 7: 373-400.
10. Siddoway L.A., Thompson K.A., McAliister C.R. et al. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences. – Circulation, 1987; 75: 785-791.
11. Lee J.T., Kroemer H.K., Silberstein D.J. et al. The role of genetically determined polymorphic drug metabolism in the b-blockade produced by propafenone. – New Engl. J. Med., 1990; 322: 1764- 1768.
12. Kessler J.M., Cubeddu L.X. Cardiovascular therapy in patients with organ failure. – In: F.H.Messerli (ed.) Cardiovascular drug therapy. – 2nd ed. – Philadelphia, 1996. – pp. 234-250.
13. Reiffel J.A., Murray K.T., Prystowsky E.N. Propafenone. — In: F.H.Messerli (ed.) Cardiovascular drug therapy. – 2nd ed. – Philadelphia, 1996. – pp. 1349-1362.
14. Seipel L., Breihard G. Propafenone – a new antiarrhythmic drug. — Europ. Heart J., 1980; 1:309-313.
15. Dukes I.D., Vaughan-Williams E.M. The multiple modes of action of propafenone. – Europ. Heart J., 1984; 5 (1):115-125.
16. Podrid P.J., Lown B. Propafenone – a new drug for ventricular arrhythmias – J. Amer. Coll.. Cardiol., 1984; 4: 117-125.
17. Valderrabano M., Singh B.N. Electrophysiologic and antiarrhythmic effect of propafenone: Focus on atrial fibrillation. – J.Cardiovasc. Pharmacol. Ther., 1984; 4: 183-198.
18. Shen E.N. Propafenone: a promising new antiarrhythmic agent. – Chest, 1990; 98: 434-441.
19. Woosley R.L. Antiarrhythmic drugs. – Annu. Rev. Pharmacol. Toxicol., 1991; 31: 427-455.
20. Kowey P.R. Pharmacological effects of antiarrhythmic drugs. Review and update. – Arch. Intern. Med., 1998; 158 (4): 325-332.
21. Thompson K.A., Iansmith D.H., Siddoway L.A. et al. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinji fibers. — J. Pharmacol. Exper. Ther., 1988; 244: 950-955.
22. Zipes D.P. Management of cardiac arrhythmias: Pharmacological, electrical and surgical techniques. – In: E.Braunwald (ed.) Heart disease. – 5th edition,- Philadelphia, 1997. – pp. 593-639.
23. Haefeli E.W., Vozeh S., Huy-Rriem H., Follath F. Comparison of pharmacodynamic effects of intravenous and oral propafenone. – Clin. Pharmacol. Therapy, 1990; 48: 245-254.
24. Horowitz L.N. Current management of arrhythmias. – Philadelphia, 1991. – pp. 357-364.
25. Prystowsky E.N., Heger J.J., Chilson D.A. et al. Antiarrhythmic and electrophysiologic effects of oral propafenone. — Amer. J. Cardiol., 1984; 54: 26D-28D.
26. Goy J.-J., Fromer M,., Kappenberger L. Electrophysiologic effects of intravenous propafenone at rest, during isoproterenol infusion and during exercise in the Wolff-Parkinson-White syndrome. – Amer. J. Cardiol., 1991; 68: 681-684.
27. Gaita F., Guistetto C., Riccardi R., Brusca A. Wolff-Parkinson-White syndrome: Identification and management. – Drugs, 1992; 43: 185- 200.
28. Cheriex E.C., Krijne R., Brugada P. et al. Lack of clinically significant β-blocking effect of propafenone. – Europ. Heart J., 1987; 8 (1):53-56.
29. Malfatto G., Pessano P., Zaza A. et al. Experimental evidence for beta-blocking properties of propafenone and for their potential clinical relevance. — Europ. Heart J., 1993; 14: 1253-1257.
30. Boriani G., Capucci A., Strocchi E. et al. β-blocking properties of propafenone in extensive oxidisers; A study on heart rate behaviour during Holter monitoring – Drug Invest., 1993; 6 (1): 25-32.
31. Bigot M.-C., Debruyne D., Bonnefoy L. et al. Serum digoxin levels related to plasma propafenone levels during concomitant treament. – J. Clin. Pharmacol., 1991; 31: 521-526.
32. Lee B.L., Dohrmann M.L. Theophylline toxicity after propafenone: Evidence for drug interaction. – Clin. Pharmacol. Therapy, 1991; 52: 353-355.
33. Kishore A.G.R., Camm A.J. Guidelines for the use of propafenone in treating supraventricular arrhythmias. – Drugs, 1995; 50 (2): 250-262.